查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1437507

视网膜生物製品市场，按药物类别、适应症、配销通路、国家和地区 - 2024-2032 年行业分析、市场规模、市场份额和预测

Retinal Biologics Market, By Drug Class, By Indication, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 322 Pages | 商品交期: 2-3个工作天内

价格

报告要点

2023 年，视网膜生物製品市场规模为 223.45 亿美元，2024 年至 2032 年复合CAGR为 7.5%。

视网膜生物製品市场-市场动态

糖尿病和黄斑部病变盛行率上升推动市场需求

全球糖尿病和黄斑部病变的盛行率不断上升，预计将在预测期内推动视网膜生物製品市场的发展。例如，根据糖尿病研究所基金会发表的资料，11.3%的美国人，即3,730万人患有糖尿病。预计有 2870 万人被诊断出患有糖尿病。全球有 860 万人患有糖尿病，但尚未意识到自己的病情。同样，根据CDC提供的资料，2019年40岁以上的美国人有1980万（占总人口的12.6%）患有年龄相关性黄斑部病变（AMD）。因此，上述统计数据预计将推动该公司的收入增长。市场。

视网膜生物製剂市场 - 关键见解

根据我们的研究分析师分享的分析，预计全球市场在预测期内（2024-2032）每年将以 7.5% 左右的CAGR成长

基于药物类别细分，VEGF-A拮抗剂领域占市场主导地位

根据适应症细分，黄斑部病变在 2023 年占据最大市场份额

基于配销通路细分，医院药房占据市场主导地位

按地区划分，北美是 2023 年的主要收入来源

视网膜生物製品市场-区隔分析：

全球视网膜生物製品市场根据药物类别、适应症、配销通路和地区进行细分。

根据药物类别，市场分为两类：TNF-a抑制剂和VEGF-A拮抗剂。 VEGF-A 拮抗剂领域在市场上占据主导地位。该细分市场的扩张归因于产品批准的不断增长。例如，诺华公司透露，Beovu（R）（brolucizumab）注射液现已获得欧盟委员会（EC）授权用于治疗湿性老年黄斑部病变（AMD）。 Beovu 是第一个获得欧盟委员会许可的抗VEGF 药物，与阿柏西普（次要终点）相比，它显示出更好的视网膜液（IRF/SRF）分辨率，这是疾病活动的关键指标。

市场依适应症分为四类：糖尿病视网膜病变、黄斑部病变、葡萄膜炎等。黄斑部病变在 2023 年占据最大的市场份额，并且由于针对黄斑部病变开发的药物数量不断增加以及黄斑部病变的全球发病率不断上升，预计在预测期内将继续保持相同的格局。例如，国家医学图书馆 2022 年 9 月发布的研究预测，到 2040 年，全球将有超过 3 亿人患有年龄相关性黄斑部病变 (AMD)。

根据配销通路，市场分为三类：医院药房、零售药房和网路药房。医院药房在市场上占据主导地位，并且由于各种药物的供应，在预测期内可能会保持其主导地位。

视网膜生物製剂市场 - 地理洞察

从地理来看，该市场广泛分布于北美、拉丁美洲、欧洲、亚太、中东和非洲等地区。这些区域根据开展业务的国家进一步划分。预计北美将在预测期内引领视网膜生物製品市场。区域扩张归因于主要市场参与者的存在及其产品的批准。例如，2023 年 8 月，Regeneron Pharmaceuticals 的单株抗体 Veopoz (pozelimab-bbfg) 获得 FDA 授权，用于治疗 CHAPLE 病，也称为 CD55 缺陷型蛋白丢失性肠病，治疗成人和儿童患者一年。年龄更大。此外，该公司报告称，FDA 已授权Eylea HD（阿柏西普）注射液8 mg，这是Eylea 的高剂量形式，用于治疗糖尿病视网膜病变、糖尿病黄斑水肿和湿性老年黄斑部病变(wAMD )。此外，糖尿病盛行率的增加和黄斑部病变的盛行率预计将推动该地区的市场成长。

视网膜生物製品市场-竞争格局：

市场上的主要参与者包括罗氏公司、辉瑞公司、默克公司、拜耳公司、艾伯维公司、杨森生物技术公司、勃林格殷格翰国际有限公司、阿斯特捷利康公司、费森尤斯公司、梯瓦製药工业有限公司.、诺华公司、安进公司、再生元製药公司、太阳製药工业有限公司和百时美施贵宝公司。为了进入新市场，市场参与者不断采取各种策略性倡议，包括创造新产品、融资和投资、併购以及其他策略伙伴关係。

最近的发展：

2023年6月，合约开发与製造组织（CDMO）瓦克生物技术公司与再生医学治疗公司Caeregen Therapeutics将合作开发和生产CTR-107（NoregenTM），这是一种用于治疗视网膜病变的新型再生疗法。相关的视力丧失。为了促进2024年I/II期临床研究的启动，瓦克生物技术作为Caeregen CTR-107的CDMO合作伙伴，将在其位于德国哈勒的工厂生产原料药，并在其位于阿姆斯特丹的工厂完成临床试验药品的生产。 ， 荷兰人。 CTR-107 是第一个获得美国 FDA 罕见儿科疾病认定的治疗家族性渗出性玻璃体视网膜病变 (FEVR) 的计画。

目录

第一章：视网膜生物製品市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 按药物类别分類的视网膜生物製品市场片段
    • 视网膜生物製品市场片段（按适应症）
    • 按配销通路分類的视网膜生物製品市场片段
    • 按国家/地区分類的视网膜生物製品市场片段
    • 按地区分類的视网膜生物製品市场片段
  • 竞争洞察

第 3 章：视网膜生物製剂主要市场趋势

  • 视网膜生物製品市场驱动因素
    • 市场驱动因素的影响分析
  • 视网膜生物製品市场限制
    • 市场限制影响分析
  • 视网膜生物製品市场机会
  • 视网膜生物製品市场未来趋势

第 4 章：视网膜生物製品产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：视网膜生物製剂市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：视网膜生物製品市场格局

  • 2023 年视网膜生物製品市场占有率分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：视网膜生物製品市场 - 依药物类别

  • 概述
    • 按药物类别分類的细分市场份额分析
    • TNF-α抑制剂
    • VEGF-A拮抗剂

第 8 章：视网膜生物製剂市场 - 按适应症

  • 概述
    • 按指标分類的细分市场占有率分析
    • 糖尿病性视网膜病变
    • 黄斑部病变
    • 葡萄膜炎
    • 其他的

第 9 章：视网膜生物製品市场 - 按配销通路

  • 概述
    • 按配销通路分類的细分市场份额分析
    • 医院药房
    • 零售药局
    • 网路药局

第 10 章：视网膜生物製品市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美视网膜生物製品主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按药物类别）
    • 北美市场规模和预测（按指标）
    • 北美市场规模和预测（按配销通路）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲视网膜生物製品主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模和预测（按药物类别）
    • 欧洲市场规模与预测（按指标）
    • 欧洲市场规模和预测（按配销通路）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区视网膜生物製剂主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模和预测（按药物类别）
    • 亚太地区市场规模与预测（依指标）
    • 亚太地区市场规模和预测（按配销通路）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲视网膜生物製品主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（按药物类别）
    • 拉丁美洲市场规模与预测（按指标）
    • 拉丁美洲市场规模和预测（按配销通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲视网膜生物製品主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按药物类别）
    • 中东和非洲市场规模及预测（依指标）
    • 中东和非洲市场规模及预测（按配销通路）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 11 章：主要供应商分析 - 视网膜生物製品产业

  • 竞争仪表板
  • 公司简介
    • F. Hoffmann-La Roche Ltd
    • Pfizer Inc.
    • Merck & Co Inc
    • Bayer AG
    • AbbVie Inc.
    • Janssen Biotech
    • Boehringer Ingelheim International GmbH
    • AstraZeneca plc
    • Fresenius SE
    • Teva Pharmaceuticals Industries Ltd.
    • Novartis AG
    • Amgen Inc
    • Regeneron Pharmaceuticals Inc
    • Sun Pharmaceutical Industries Ltd.
    • Bristol-Myers Squibb

第 12 章：360 度分析师视角

第 13 章：附录

  • 研究方法论
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
Product Code: ANV2225

REPORT HIGHLIGHT

Retinal Biologics Market size was valued at USD 22,345 Million in 2023, expanding at a CAGR of 7.5% from 2024 to 2032.

Specialized therapeutic compounds called retinal biologics are used to treat a variety of retinal conditions, including diabetic retinopathy and macular degeneration. These biologics, which include proteins and antibodies produced from living things, are made to specifically target molecules or processes associated with retinal disorders. They provide more effective treatment alternatives than traditional techniques by offering tailored medicines that address the underlying processes of retinal diseases. Usually, intravitreal injections are used to give retinal biologics, which entail injecting the drug right into the eye.

Retinal Biologics Market- Market Dynamics

Increasing prevalence of diabetes and macular degeneration to propel market demand

The increasing prevalence of diabetes and macular degeneration across the globe is expected to drive the retinal biologics market over the forecast period. For instance, according to the data published by the Diabetes Research Institute Foundation, 11.3% of Americans, or 37.3 million individuals, suffer from diabetes. 28.7 million persons were projected to have been diagnosed with diabetes. 8.6 million people worldwide suffer from diabetes but are not yet aware of their condition. Similarly, as per the data provided by the CDC, 19.8 million Americans (or 12.6% of the population) over 40 had age-related macular degeneration (AMD) in 2019. Thus, the aforementioned statistics are expected to propel the revenue growth of the market.

Retinal Biologics Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.5% over the forecast period (2024-2032)

Based on drug class segmentation, the VEGF-A Antagonist sector dominates the market

Based on indication segmentation, the macular degeneration held the largest market share in 2023

Based on distribution channel segmentation, the hospital pharmacies dominate the market

Based on region, North America was the leading revenue generator in 2023

Retinal Biologics Market- Segmentation Analysis:

The Global Retinal Biologics Market is segmented based on Drug Class, Indication, Distribution Channel, and Region.

The market is divided into two categories based on drug class: TNF-a Inhibitor and VEGF-A Antagonist. The VEGF-A Antagonist sector dominates the market. The segment expansion is attributed to the growing product approvals. For instance, Novartis disclosed that Beovu® (brolucizumab) injection is now authorized by the European Commission (EC) to treat wet age-related macular degeneration (AMD). Beovu is the first anti-VEGF medication licensed by the European Commission that has shown better resolution of retinal fluid (IRF/SRF), a crucial indicator of disease activity, in comparison to aflibercept (secondary endpoints).

The market is divided into four categories based on indication: diabetic retinopathy, macular degeneration, uveitis and others. Macular degeneration held the largest market share in 2023 and is expected to continue the same pattern during the forecast period due to the growing number of drugs being developed for macular degeneration and the condition's increasing global incidence. For instance, in September 2022 research released by the National Library of Medicine predicted that over 300 million people worldwide will have age-related macular degeneration (AMD) by the year 2040.

The market is divided into three categories based on distribution channel: hospital pharmacies, retail pharmacies and online pharmacies. Hospital pharmacies dominate the market and are likely to maintain their dominance during the forecast period due to the availability of various types of medication.

Retinal Biologics Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to lead the retinal biologics market during the forecast period. The regional expansion is attributed to the presence of major market players and the approvals of their products. For instance, in August 2023, Veopoz (pozelimab-bbfg), a monoclonal antibody, was authorized by the FDA by Regeneron Pharmaceuticals to treat CHAPLE disease, also known as CD55-deficient protein-losing enteropathy, in adults and pediatric patients one year of age and older. Additionally, the firm reported that the FDA has authorized Eylea HD (aflibercept) Injection 8 mg, a high-dose form of Eylea, for the treatment of diabetic retinopathy, diabetic macular edema, and wet age-related macular degeneration (wAMD). Furthermore, the increasing prevalence of diabetes and the prevalence of macular degeneration is expected to propel the market growth in the region.

Retinal Biologics Market- Competitive Landscape:

The key players operating in the market are F. Hoffmann-La Roche Ltd, Pfizer Inc., Merck & Co Inc, Bayer AG, AbbVie Inc., Janssen Biotech, Boehringer Ingelheim International GmbH, AstraZeneca plc, Fresenius SE, Teva Pharmaceuticals Industries Ltd., Novartis AG, Amgen Inc, Regeneron Pharmaceuticals Inc, Sun Pharmaceutical Industries Ltd. and Bristol-Myers Squibb. To obtain access to new markets, market players are continuously pursuing a variety of strategic initiatives, including the creation of new products, funding and investments, mergers and acquisitions, and other strategic partnerships.

Recent Developments:

In June 2023, Wacker Biotech, a contract development and manufacturing organization (CDMO), and Caeregen Therapeutics, a regenerative medicine therapeutics company, will work together to develop and produce CTR-107 (NoregenTM), a novel regenerative therapeutic for the treatment of retinal-related vision loss. To facilitate the start of Phase I/II clinical studies in 2024, Wacker Biotech, as Caeregen's CDMO partner for CTR-107, will create drug substance at its location in Halle, Germany, and complete clinical trial drug product manufacturing at its location in Amsterdam, the Netherlands. The first program to treat familial exudative vitreoretinopathy (FEVR) to get a Rare Pediatric Disease Designation from the US FDA is CTR-107.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL RETINAL BIOLOGICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

F. Hoffmann-La Roche Ltd

Pfizer Inc.

Merck & Co. Inc

Bayer AG

AbbVie Inc.

Janssen Biotech

Boehringer Ingelheim International GmbH

AstraZeneca plc

Fresenius SE

Teva Pharmaceuticals Industries Ltd.

Novartis AG

Amgen Inc

Regeneron Pharmaceuticals Inc

Sun Pharmaceutical Industries Ltd.

Bristol-Myers Squibb

GLOBAL RETINAL BIOLOGICS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • TNF-a Inhibitor
  • VEGF-A Antagonist

GLOBAL RETINAL BIOLOGICS MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Diabetic Retinopathy
  • Macular Degeneration
  • Uveitis
  • Others

GLOBAL RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL RETINAL BIOLOGICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Retinal Biologics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Retinal Biologics Market Snippet by Drug Class
    • 2.1.2. Retinal Biologics Market Snippet by Indication
    • 2.1.3. Retinal Biologics Market Snippet by Distribution Channel
    • 2.1.4. Retinal Biologics Market Snippet by Country
    • 2.1.5. Retinal Biologics Market Snippet by Region
  • 2.2. Competitive Insights

3. Retinal Biologics Key Market Trends

  • 3.1. Retinal Biologics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Retinal Biologics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Retinal Biologics Market Opportunities
  • 3.4. Retinal Biologics Market Future Trends

4. Retinal Biologics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Retinal Biologics Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Retinal Biologics Market Landscape

  • 6.1. Retinal Biologics Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Retinal Biologics Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
    • 7.1.2. TNF-a Inhibitor
    • 7.1.3. VEGF-A Antagonist

8. Retinal Biologics Market - By Indication

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
    • 8.1.2. Diabetic Retinopathy
    • 8.1.3. Macular Degeneration
    • 8.1.4. Uveitis
    • 8.1.5. Others

9. Retinal Biologics Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Retail Pharmacies
    • 9.1.4. Online Pharmacies

10. Retinal Biologics Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Retinal Biologics Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Retinal Biologics Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Retinal Biologics Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Retinal Biologics Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Retinal Biologics Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Retinal Biologics Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. F. Hoffmann-La Roche Ltd
    • 11.2.2. Pfizer Inc.
    • 11.2.3. Merck & Co Inc
    • 11.2.4. Bayer AG
    • 11.2.5. AbbVie Inc.
    • 11.2.6. Janssen Biotech
    • 11.2.7. Boehringer Ingelheim International GmbH
    • 11.2.8. AstraZeneca plc
    • 11.2.9. Fresenius SE
    • 11.2.10. Teva Pharmaceuticals Industries Ltd.
    • 11.2.11. Novartis AG
    • 11.2.12. Amgen Inc
    • 11.2.13. Regeneron Pharmaceuticals Inc
    • 11.2.14. Sun Pharmaceutical Industries Ltd.
    • 11.2.15. Bristol-Myers Squibb

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Retinal Biologics Market: Drug Class Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Drug Class
  • TABLE Global Retinal Biologics Market, by Drug Class 2019-2032 (USD Million)
  • TABLE Retinal Biologics Market: Indication Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Indication
  • TABLE Global Retinal Biologics Market, by Indication 2019-2032 (USD Million)
  • TABLE Retinal Biologics Market: Distribution Channel Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Distribution Channel
  • TABLE Global Retinal Biologics Market, by Distribution Channel 2019-2032 (USD Million)
  • TABLE Retinal Biologics Market: Regional snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Retinal Biologics Market, by Region 2019-2032 (USD Million)
  • TABLE North America Retinal Biologics Market, by Country, 2019-2032 (USD Million)
  • TABLE North America Retinal Biologics Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE North America Retinal Biologics Market, by Indication, 2019-2032 (USD Million)
  • TABLE North America Retinal Biologics Market, by Distribution Channel, 2019-2032 (USD Million)
  • TABLE Europe Retinal Biologics Market, by Country, 2019-2032 (USD Million)
  • TABLE Europe Retinal Biologics Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE Europe Retinal Biologics Market, by Indication, 2019-2032 (USD Million)
  • TABLE Europe Retinal Biologics Market, by Distribution Channel, 2019-2032 (USD Million)
  • TABLE Asia Pacific Retinal Biologics Market, by Country, 2019-2032 (USD Million)
  • TABLE Asia Pacific Retinal Biologics Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE Asia Pacific Retinal Biologics Market, by Indication, 2019-2032 (USD Million)
  • TABLE Asia Pacific Retinal Biologics Market, by Distribution Channel, 2019-2032 (USD Million)
  • TABLE Latin America Retinal Biologics Market, by Country, 2019-2032 (USD Million)
  • TABLE Latin America Retinal Biologics Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE Latin America Retinal Biologics Market, by Indication, 2019-2032 (USD Million)
  • TABLE Latin America Retinal Biologics Market, by Distribution Channel, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Retinal Biologics Market, by Country, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Retinal Biologics Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Retinal Biologics Market, by Indication, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Retinal Biologics Market, by Distribution Channel, 2019-2032 (USD Million)